

## Oncaspar

## **Prior Authorization Request**

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756 to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4.

Patient's Name:	Date:
Patient's ID:	Patient's Date of Birth:
Physician's Name:	
Specialty:	NPI#:
Physician Office Telephone:	Physician Office Fax:
Referring Provider Info:   Same as Requesting Provider	ider
Name:	NPI#:
Fax:	Phone:
Rendering Provider Info:  Same as Referring Provided Name:	
Fax:	Phone:
accepted compendia, and/or e Required Demographic Information:	evidence-based practice guidelines.
Patient Weight:kg	
Patient Height:cm	
Please indicate the place of service for the requested drug  ☐ Ambulatory Surgical (POS Code 24)  ☐ Off Campus Outpatient Hospital (POS Code 19)  ☐ Office (POS Code 11)	☐ Home (POS Code 12) ☐ On Campus Outpatient Hospital (POS Code 22)
Drug Information:	
Strength/Measure	_Units □ ml □ Gm □ mg □ ea □ Un
	Route of administration
Dosing frequency	
What is the ICD-10 code?	
Criteria Questions:	
1. What is the diagnosis?	
☐ Acute lymphoblastic leukemia (ALL), Continue to 2	
☐ Lymphoblastic lymphoma (LL), Continue to 2	
☐ Extranodal natural killer/T-cell lymphoma (ENKL), C	Continue to 2

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oncaspar SGM 2291-A – 02/2024.



2. Is this a request for continuation of therapy with the requested medication?    Yes, Continue to 3   No, Continue to 4  3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?   Yes, No Further Questions   No, No Further Questions   Acute lymphoblastic leukemia (ALL), Continue to 6   Lymphoblastic lymphoma (LL), Continue to 6   Extranodal natural killer/T-cell lymphoma (ENKL), Continue to 6   Aggressive NK-cell leukemia (ANKL), Continue to 6   Hepatosplenic T-cell lymphoma, Continue to 5  5. What is the place in therapy in which the requested medication will be used?   First-line treatment, Continue to 6   Subsequent treatment, Continue to 6   Will the requested medication be used in conjunction with multi-agent chemotherapy?   Yes, No Further Questions   No, No Further Questions	rescriber or Authorized Signature	Date (mm/dd/yy)
<ul> <li>2. Is this a request for continuation of therapy with the requested medication?  Yes, Continue to 3  No, Continue to 4</li> <li>3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?  Yes, No Further Questions  No, No Further Questions</li> <li>4. What is the diagnosis?  Acute lymphoblastic leukemia (ALL), Continue to 6  Lymphoblastic lymphoma (LL), Continue to 6  Extranodal natural killer/T-cell lymphoma (ENKL), Continue to 6  Aggressive NK-cell leukemia (ANKL), Continue to 6</li> <li>Hepatosplenic T-cell lymphoma, Continue to 5</li> <li>5. What is the place in therapy in which the requested medication will be used?  First-line treatment, Continue to 6</li> <li>Subsequent treatment, Continue to 6</li> <li>6. Will the requested medication be used in conjunction with multi-agent chemotherapy?  Yes, No Further Questions</li> </ul>		
2. Is this a request for continuation of therapy with the requested medication?  □ Yes, Continue to 3 □ No, Continue to 4  3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?  □ Yes, No Further Questions □ No, No Further Questions  4. What is the diagnosis? □ Acute lymphoblastic leukemia (ALL), Continue to 6 □ Lymphoblastic lymphoma (LL), Continue to 6 □ Extranodal natural killer/T-cell lymphoma (ENKL), Continue to 6 □ Aggressive NK-cell leukemia (ANKL), Continue to 6 □ Hepatosplenic T-cell lymphoma, Continue to 5  5. What is the place in therapy in which the requested medication will be used? □ First-line treatment, Continue to 6 □ Subsequent treatment, Continue to 6  6. Will the requested medication be used in conjunction with multi-agent chemotherapy? □ Yes, No Further Questions		
<ul> <li>2. Is this a request for continuation of therapy with the requested medication?  Yes, Continue to 3  No, Continue to 4</li> <li>3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?  Yes, No Further Questions  No, No Further Questions</li> <li>4. What is the diagnosis?  Acute lymphoblastic leukemia (ALL), Continue to 6  Lymphoblastic lymphoma (LL), Continue to 6  Extranodal natural killer/T-cell lymphoma (ENKL), Continue to 6  Aggressive NK-cell leukemia (ANKL), Continue to 6</li> <li>Hepatosplenic T-cell lymphoma, Continue to 5</li> <li>5. What is the place in therapy in which the requested medication will be used?  First-line treatment, Continue to 6</li> </ul>	☐ Yes, No Further Questions	on with multi-agent chemotherapy?
<ul> <li>2. Is this a request for continuation of therapy with the requested medication?</li> <li>Yes, Continue to 3</li> <li>No, Continue to 4</li> <li>3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?</li> <li>Yes, No Further Questions</li> <li>No, No Further Questions</li> <li>4. What is the diagnosis?</li> <li>Acute lymphoblastic leukemia (ALL), Continue to 6</li> <li>Lymphoblastic lymphoma (LL), Continue to 6</li> <li>Extranodal natural killer/T-cell lymphoma (ENKL), Continue to 6</li> <li>Aggressive NK-cell leukemia (ANKL), Continue to 6</li> </ul>	☐ First-line treatment, Continue to 6	medication will be used?
<ul> <li>2. Is this a request for continuation of therapy with the requested medication?  Yes, Continue to 3  No, Continue to 4</li> <li>3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?  Yes, No Further Questions  No, No Further Questions</li> <li>4. What is the diagnosis?  Acute lymphoblastic leukemia (ALL), Continue to 6  Lymphoblastic lymphoma (LL), Continue to 6</li> </ul>	, , , ,	o 6
<ul> <li>2. Is this a request for continuation of therapy with the requested medication?</li> <li>Yes, Continue to 3</li> <li>No, Continue to 4</li> <li>3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?</li> <li>Yes, No Further Questions</li> <li>No, No Further Questions</li> <li>4. What is the diagnosis?</li> <li>Acute lymphoblastic leukemia (ALL), Continue to 6</li> </ul>	☐ Extranodal natural killer/T-cell lymphoma (ENKL)	, Continue to 6
<ul> <li>2. Is this a request for continuation of therapy with the requested medication?</li> <li>Yes, Continue to 3</li> <li>No, Continue to 4</li> <li>3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?</li> <li>Yes, No Further Questions</li> <li>No, No Further Questions</li> <li>4. What is the diagnosis?</li> </ul>		
<ul> <li>2. Is this a request for continuation of therapy with the requested medication?</li> <li>Yes, Continue to 3</li> <li>No, Continue to 4</li> <li>3. Is there evidence of unacceptable toxicity or disease progression while on the current regimen?</li> <li>Yes, No Further Questions</li> </ul>	_	6
<ul> <li>2. Is this a request for continuation of therapy with the requested medication?</li> <li>☐ Yes, Continue to 3</li> </ul>	☐ Yes, No Further Questions	e progression while on the current regimen?
	$\square$ Yes, Continue to 3	1
	· · · · · ·	
		. Continue to 2
☐ Aggressive NK-cell leukemia (ANKL), <i>Continue to 2</i> ☐ Hepatosplenic T-cell lymphoma, <i>Continue to 2</i>		0.2

Send completed form to: Priority Partners Fax: 1-866-212-4756

Note: This fax may contain medical information that is privileged and confidential and is solely for the use of individuals named above. If you are not the intended recipient you hereby are advised that any dissemination, distribution, or copying of this communication is prohibited. If you have received the fax in error, please immediately notify the sender by telephone and destroy the original fax message. Oncaspar SGM 2291-A – 02/2024.